

February 6, 2026

To,

<b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400 001 Scrip Code (BSE): 544009	<b>National Stock Exchange of India Limited</b> “Exchange Plaza” Bandra-Kurla Complex, Bandra (East) Mumbai - 400051 Symbol: BLUEJET
---	--

**Sub: Intimation of Analyst and Investor call under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir / Ma'am,

In terms of the referred Regulation 30 read with Schedule III - Part A of SEBI Listing Regulations, 2015, we would like to inform you that a conference call for group of analysts and investors has been scheduled on Friday, February 13, 2026, at 5:00 PM (IST) to discuss the Unaudited Standalone Financial Results of the Company for the quarter and nine months ended December 31, 2025.

Details of the conference call are enclosed for your kind reference.

You are requested to take the same on record.

Thanking you,

Yours faithfully,  
For Blue Jet Healthcare Limited

**Sweta Poddar**  
Company Secretary & Compliance Officer

**PRESS RELEASE**

For Immediate dissemination



## Blue Jet Healthcare Limited

### Q3 & 9M FY26 Earnings Call on February 13, 2026, at 5:00 PM IST

**Mumbai, February 6, 2026:** Blue Jet Healthcare Ltd. (BSE- 544009, NSE- BLUEJET, ISIN: INE0KBH01020), a global, science-led, pharmaceutical company evolved as Strategic Partner for Collaboration, Development & Manufacturing of advance Pharmaceutical Intermediates and API, will host earnings call to discuss financial results for the quarter and nine month ended 31<sup>st</sup> December 2025 on **Friday, February 13, 2026, at 5:00 PM (IST)**.

<b>Details of Earnings Conference Call</b>	
<b>Day/Date</b>	Friday, February 13, 2026
<b>Time (IST)</b>	5:00 PM
<b>Universal Access</b>	+91 22 6280 1107 +91 22 7115 8008
<i>The number listed above is universally accessible from all networks and all countries</i>	
<b>International Toll-Free Numbers</b>	
USA	18667462133
UK	08081011573
Singapore	8001012045
Hong Kong	800964448
DiamondPass™ Link	<a href="#">Click here</a> to join with DiamondPass™ (No Wait Time)
<b>Management Representation:</b>	
Mr. Shiven Arora - Managing Director	
Mr. V.K. Singh - Chief Operating Officer	
Mr. Ganesh Karuppannan - Chief Financial Officer	
Mr. Sanjay Sinha - Deputy Chief Financial Officer	
<i>Participants are requested to dial-in 10 minutes before the scheduled time</i>	

**About Blue Jet Healthcare Ltd:**

Blue Jet Healthcare Ltd a specialty pharmaceutical and healthcare ingredient and intermediate company, operating under a contract development and manufacturing organization ("CDMO") business model. The company has specialized chemistry capabilities in contrast media intermediates and high-intensity sweeteners. They have built a long-term customer base with innovator and multi-national generic pharmaceutical companies, supported by multi-year contracts. They supply a critical starting intermediate and several advanced intermediates to three of the largest contrast media manufacturers in the world, including GE Healthcare, Guerbet, and Bracco. They also supply high-intensity sweeteners to several multi-national companies, including Colgate Palmolive (India) Limited and Unilever.

**For further details, please get in touch with:****Ms. Sweta Poddar**

Blue Jet Healthcare Ltd

Email: [companysecretary@bluejethealthcare.com](mailto:companysecretary@bluejethealthcare.com)**Diwakar Pingle | Kunal Bhoite**

EY Investor Relations

Email: [diwakar.pingle@in.ey.com](mailto:diwakar.pingle@in.ey.com) | [kunal.bhoite@in.ey.com](mailto:kunal.bhoite@in.ey.com)